ArticleHeart (British Cardiac Society)2024
Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease.
Article in Heart (British Cardiac Society), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Methods to assess atherosclerotic cardiovascular risk in chronic respiratory diseases: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Prevalence and Risk Factors of Arrhythmias in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Cardiovascular and mortality risks following COVID-19-related versus non-COVID-19-related chronic obstructive pulmonary disease exacerbations.Annals of the American Thoracic Society · 2026Article
- An Age-Friendly Approach to Caring for Chronic Lung Disease in the Ambulatory Setting.Respirology (Carlton, Vic.) · 2026Review
- Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.Seminars in respiratory and critical care medicine · 2026Review
- Article
- Beyond Triple Therapy: Anti-Type 2 Biologic Therapies for Eosinophilic COPD and Respiratory Comorbidities - a Review of Clinical Evidence.Current allergy and asthma reports · 2026Review
- Latent profiles of caregiver self-care contributions for patients with COPD: a multicenter cross-sectional study.BMC nursing · 2026Article
- Long-term cardiovascular risk after severe exacerbation of COPD: a population-based cohort study.ERJ open research · 2026Article
- Association of the advanced lung cancer inflammation index and controlling nutritional status score with atrial fibrillation in COPD patients: a multicenter cross-sectional study.Frontiers in nutrition · 2026Article
- Temporal trends in stroke-prevention medication use in patients with atrial fibrillation and chronic obstructive pulmonary disease.Frontiers in pharmacology · 2026Article
- Evaluation of the impact of cardiopulmonary rehabilitation exercise training on cardiopulmonary function in patients with chronic obstructive pulmonary disease complicated by unstable angina pectoris using a hierarchical deep learning CT image model.Frontiers in physiology · 2026Article
- Cardiopulmonary risk in the COPD patient: the EPOCONSUL audit.Scientific reports · 2025Article
- Association between multimorbidity and disability among elderly with chronic obstructive pulmonary disease in Shanghai, China: a cross-sectional study.BMC geriatrics · 2025Article
- The impact of socio-economic deprivation on the long-term survival of people with diabetes and acute myocardial infarction: A nationwide cohort study.Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Healthcare resource utilisation in patients with exacerbations of COPD and associated cardiovascular events: the EXACOS-CV study.ERJ open research · 2025Article
- Automated Chronic Obstructive Pulmonary Disease Phenotyping and Control Assessment in Primary Care: Retrospective Multicenter Study Using the Seleida Model.JMIR medical informatics · 2025Article
- Cardiovascular safety of biologic therapies in patients with severe asthma: a nationwide cohort study in Belgium.The Lancet regional health. Europe · 2025Article
- Long-term outcomes of patients with pre-existing coronary artery disease after SARS-CoV-2 infection.EBioMedicine · 2025Article
- PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis.Drugs · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the risk of adverse cardiovascular (CV) events following an exacerbation of chronic obstructive pulmonary disease (COPD).
methodsThis retrospective cohort study identified patients with COPD using administrative data from Alberta, Canada from 2014 to 2019. Exposure periods were 12 months following moderate or severe exacerbations; the reference period was time preceding a first exacerbation. The primary outcome was the composite of all-cause death or a first hospitalisation for acute coronary syndrome, heart failure (HF), arrhythmia or cerebral ischaemia. Time-dependent Cox regression models estimated covariate-adjusted risks associated with six exposure subperiods following exacerbation.
resultsAmong 1 42 787 patients (mean age 68.1 years and 51.7% men) 61 981 (43.4%) experienced at least one exacerbation and 34 068 (23.9%) died during median follow-up of 64 months. The primary outcome occurred in 43 564 (30.5%) patients with an incidence rate prior to exacerbation of 5.43 (95% CI 5.36 to 5.50) per 100 person-years. This increased to 95.61 per 100 person-years in the 1-7 days postexacerbation (adjusted HR 15.86, 95% CI 15.17 to 16.58) and remained increased for up to 1 year. The risk of both the composite and individual CV events was increased following either a moderate or a severe exacerbation, though greater and more prolonged following severe exacerbation. The highest magnitude of increased risk was observed for HF decompensation (1-7 days, HR 72.34, 95% CI 64.43 to 81.22).
conclusionModerate and severe COPD exacerbations are independent risk factors for adverse CV events, especially HF decompensation. The impact of optimising COPD management on CV outcomes should be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.